Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population‐Based Study

Aviña‐Zubieta, J Antonio; To, Fergus; Vostretsova, Kateryna; Vera, Mary A. De; Sayre, Eric C.; Esdaile, John M.

doi:10.1002/acr.23018

Cited by 135 publications

(127 citation statements)

References 30 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…11 In addition, an association between increased incidence of CVD and chronic inflammatory disorders has been observed in several epidemiologic studies. 12–14 Chronic inflammation is not accounted for in either FRS or ACC/AHA risk score, which could be the explanation for the underestimation of the CVD risk in patients with these diseases.…”

Section: Discussionmentioning

confidence: 99%

Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis

Ungprasert

Matteson

Crowson

2017

The American Journal of Cardiology

View full text Add to dashboard Cite

Chronic inflammation is an independent risk factor for cardiovascular disease (CVD) but most risk calculators including Framingham risk score (FRS) and American College of Cardiology (ACC)/American Heart Association (AHA) risk score do not account for it. These calculators underestimate cardiovascular (CV) risk in patients with rheumatoid arthritis and systemic lupus erythematosus. To date, how these scores perform in estimation of CVD risk in patients with sarcoidosis has not been assessed. In this study, FRS and ACC/AHA risk score were calculated for a previously identified cohort of patients with incident cases of sarcoidosis in Olmsted County, Minnesota, United States from 1989 to 2013 as well as their sex and age-matched comparators. The standardized incidence ratio (SIR) was estimated as the ratio of the predicted and observed number of CVD events. All CVD events were identified by diagnosis codes and verified by individual medical record review. The predicted number of CVD events among 188 cases by FRS was 11.8 and the observed number of CVD events was 34, which corresponding to an SIR of 2.88 (95% CI, 2.06 – 4.04). FRS underestimated the risk of CVD events in patients with sarcoidosis by sex, age and severity of sarcoidosis. The predicted number of CVD events among cases by ACC/AHA risk score was 4.6 and the observed number of CVD events was 19, corresponding to an SIR of 4.11 (95% CI, 2.62 – 6.44). In conclusion, FRS and ACC/AHA risk score underestimate the risk of CVD among patients with sarcoidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis

Ungprasert

Matteson

Crowson

2017

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Systemic lupus erythematosus (SLE) is associated with multiple morbidities and premature mortality (1)(2)(3)(4)(5). Lupus nephritis (LN) affects ~50% of adults with SLE, and despite the introduction of improved, lower-toxicity treatments in the past 15 years, including mycophenolate and low-dose cyclophosphamide regimens (6)(7)(8), up to 30% of patients with LN develop end-stage renal disease (ESRD) (9).…”

Section: Introductionmentioning

confidence: 99%

All‐Cause and Cause‐Specific Mortality Trends of End‐Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014

Jorge

Wallace

Zhang

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Furthermore, SLE constitutes an independent risk factor for mortality and impaired recovery after an ischaemic event [4,13]. Cerebral and cardiovascular events can complicate the underlying inflammatory disease at any time, but the early stages of the disease seem to be associated with a higher age-adjusted risk of vascular complications [14][15][16]. Nonetheless, the excess prevalence of ischaemic manifestations in patients with SLE increases with time in comparison to control subjects [17].…”

Section: Introductionmentioning

confidence: 99%

Under crossfire: thromboembolic risk in systemic lupus erythematosus

et al. 2018

View full text Add to dashboard Cite

Cerebral and cardiovascular ischaemic events are frequent complications of systemic lupus erythematosus (SLE) and constitute primary causes of permanent damage. However, the pathogenic determinants of an increased thromboembolic risk in patients with SLE are only partially understood. Atherosclerosis constitutes a fertile soil for the development of thrombosis and shows disproportionately high prevalence and progression rates in patients with SLE. Antiphospholipid antibodies are independent risk factors for acute thrombosis, but can also prompt long-term vascular inflammation. Aberrant interactions among immune cells and dysfunctions in the deployment of the coagulation cascade have historically less been explored in SLE, but recent evidence suggests they can also play a critical role at the crossroads between inflammation and haemostasis. In this review, we discuss how different pro-thrombotic mechanisms can be prompted by and synergise with SLEspecific pathogenic events and speculate about novel potential directions for research and drug development.

show abstract

Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population‐Based Study

Abstract: Patients with SLE have an increased risk of cardiovascular events, particularly during the first year after diagnosis. Increased vigilance in monitoring for these potentially fatal outcomes and their modifiable risk factors is recommended in this patient population.

Cited by 135 publications

References 30 publications

Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis

Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis

All‐Cause and Cause‐Specific Mortality Trends of End‐Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014

Under crossfire: thromboembolic risk in systemic lupus erythematosus

Contact Info

Product

Resources

About